z-logo
open-access-imgOpen Access
Formulation and Evaluation of Polymeric Nanoparticles of Felodipine
Author(s) -
A Manikkavasagan
Publication year - 2022
Publication title -
saudi journal of medical and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2413-4929
pISSN - 2413-4910
DOI - 10.36348/sjmps.2022.v08i02.001
Subject(s) - dispersity , nanoparticle , solubility , zeta potential , particle size , chemical engineering , materials science , chemistry , polymer , chromatography , nanotechnology , organic chemistry , polymer chemistry , engineering
Objective: The objective of the present study was to formulate and evaluate polymeric nanoparticles of Felodipine by Nano precipitation technique using EudragitL100 and EudragitS100 as a polymers. The nanoparticles were characterized for particle size, poly-dispersity index, entrapment efficiency (EE), zeta potential, solubility, morphological study, invitro study, Ex vivo intestinal permeability studies and stability studies. Infrared studies showed that there was no drug excipients interaction. Negative values of zetapotential indicated the good stabilization of the prepared nanoparticles. Solubility measurement studies revealed that the solubility of nanoparticles was increased to ten times than the pure drug. The entrapment efficiency was found in between 29.72 ± 3.27% – 63.95 ± 3.50%. The in-vitro drug release was extended maximum up to 12 hrs with Eudragit L100. The curve fitting data shows that the drug release followed first order kinetics, Higuchi’s plots stated non-fickian diffusion controlled. The intestinal permeability of formulated nanoparticles were found to be more than pure drug. SEM shows that nanoparticles were found spherical in structure without aggregation and uniform distribution of the drug within the nanoparticles. Accelerated stability studies were also carried out following ICH Guidelines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here